These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16916873)

  • 1. Accuracy and performance of a commercially available Dosing Aid.
    Cronin TH; Kahook MY; Lathrop KL; Noecker RJ
    Br J Ophthalmol; 2007 Apr; 91(4):497-9. PubMed ID: 16916873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TRAVATAN Dosing Aid accurately records when drops are taken.
    Friedman DS; Jampel HD; Congdon NG; Miller R; Quigley HA
    Am J Ophthalmol; 2007 Apr; 143(4):699-701. PubMed ID: 17386285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid.
    Ajit RR; Fenerty CH; Henson DB
    Eye (Lond); 2010 Aug; 24(8):1338-43. PubMed ID: 20339390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study.
    Okeke CO; Quigley HA; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Friedman DS
    Ophthalmology; 2009 Feb; 116(2):191-9. PubMed ID: 19084273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Xal-Ease latanoprost delivery system.
    Semes L; Shaikh AS
    Optometry; 2007 Jan; 78(1):30-3. PubMed ID: 17208672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops.
    Boden C; Sit A; Weinreb RN
    J Glaucoma; 2006 Feb; 15(1):30-4. PubMed ID: 16378015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring adherence rates in glaucoma patients using the Travatan Dosing Aid. A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination.
    Rossi GC; Pasinetti GM; Scudeller L; Tinelli C; Milano G; Bianchi PE
    Expert Opin Pharmacother; 2010 Mar; 11(4):499-504. PubMed ID: 20163264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.
    Friedman DS; Okeke CO; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Quigley HA
    Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.
    Flowers B; Wand M; Piltz-Seymour J; Berke SJ; Day D; Teague J; Smoot TM; Landry TA; Bergamini MV; Mallick S;
    Clin Ther; 2006 Nov; 28(11):1803-11. PubMed ID: 17213000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compliance with timolol treatment in glaucoma.
    Rotchford AP; Murphy KM
    Eye (Lond); 1998; 12 ( Pt 2)():234-6. PubMed ID: 9683946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of eyedrop instillation technique with and without a delivery device in inexperienced patients.
    Gomes BF; Lordello M; Celli LF; Santhiago MR; Moraes HV
    Eur J Ophthalmol; 2016 Nov; 26(6):594-597. PubMed ID: 27135092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Improved eyedrop administration and compliance in glaucoma patients. A clinical study].
    Busche S; Gramer E
    Klin Monbl Augenheilkd; 1997 Oct; 211(4):257-62. PubMed ID: 9445914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The influence of the Travalert(®) dosing aid on medical treatment compliance and the quality of life of glaucoma patients].
    Sánchez-Pulgarín M; Martínez-de-la-Casa JM; Escalada A; Sáenz-Francés F; García-Feijoó J; García Sánchez J
    Arch Soc Esp Oftalmol; 2011 Sep; 86(9):282-6. PubMed ID: 21893261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Travoprost/timolol fixed combination.
    Herceg M; Noecker R
    Expert Opin Pharmacother; 2008 Apr; 9(6):1059-65. PubMed ID: 18377347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata.
    Ochoa BE; Sah D; Wang G; Stamper R; Price VH
    J Am Acad Dermatol; 2009 Sep; 61(3):530-2. PubMed ID: 19700021
    [No Abstract]   [Full Text] [Related]  

  • 16. A novel eye drop application monitor to assess patient compliance with a prescribed regimen: a pilot study.
    Eaton AM; Gordon GM; Konowal A; Allen A; Allen M; Sgarlata A; Gao G; Wafapoor H; Avery RL
    Eye (Lond); 2015 Oct; 29(10):1383-91. PubMed ID: 26358235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analog medication in glaucoma.
    Holló G; Kóthy P; Géczy A; Vargha P
    J Glaucoma; 2009; 18(4):288-92. PubMed ID: 19365193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
    Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata.
    Roseborough I; Lee H; Chwalek J; Stamper RL; Price VH
    J Am Acad Dermatol; 2009 Apr; 60(4):705-6. PubMed ID: 19293023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.